[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PL2295039T3 - Metoda wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tą metodą granulki zawierające pankreatynę - Google Patents

Metoda wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tą metodą granulki zawierające pankreatynę

Info

Publication number
PL2295039T3
PL2295039T3 PL10150491T PL10150491T PL2295039T3 PL 2295039 T3 PL2295039 T3 PL 2295039T3 PL 10150491 T PL10150491 T PL 10150491T PL 10150491 T PL10150491 T PL 10150491T PL 2295039 T3 PL2295039 T3 PL 2295039T3
Authority
PL
Poland
Prior art keywords
pancreatin
pellets
preparing
micropellets
prepared
Prior art date
Application number
PL10150491T
Other languages
English (en)
Other versions
PL2295039T5 (pl
Inventor
Manfred Kurfürst
Thomas Moest
Walter Doleschal
Original Assignee
Nordmark Arzneimittel Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42330999&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2295039(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nordmark Arzneimittel Gmbh & Co Kg filed Critical Nordmark Arzneimittel Gmbh & Co Kg
Publication of PL2295039T3 publication Critical patent/PL2295039T3/pl
Publication of PL2295039T5 publication Critical patent/PL2295039T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL10150491.8T 2009-08-28 2010-01-12 Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę PL2295039T5 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE202009011699 2009-08-28
EP10150491.8A EP2295039B2 (de) 2009-08-28 2010-01-12 Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets

Publications (2)

Publication Number Publication Date
PL2295039T3 true PL2295039T3 (pl) 2014-05-30
PL2295039T5 PL2295039T5 (pl) 2023-02-27

Family

ID=42330999

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10150491.8T PL2295039T5 (pl) 2009-08-28 2010-01-12 Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę

Country Status (6)

Country Link
US (1) US8999394B2 (pl)
EP (1) EP2295039B2 (pl)
JP (1) JP5761635B2 (pl)
BR (1) BRPI1000679A2 (pl)
DE (1) DE202010004926U1 (pl)
PL (1) PL2295039T5 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en) * 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
AU2010203714C1 (en) 2009-01-06 2013-12-12 Galenagen, Llc Compositions and methods for the treatment or the prevention of infections by e. coli
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
ES2488407T3 (es) 2009-01-29 2014-08-27 Nordmark Arzneimittel Gmbh & Co. Kg Preparación farmacéutica que contiene lipasa de origen bacteriano
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
PL2489349T3 (pl) * 2011-02-17 2014-09-30 Nordmark Arzneimittel Gmbh & Co Kg Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
DE102017104482A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189948A (en) * 1938-10-31 1940-02-13 Griffith Laboratories Sterilization of pancreatin
DE2923279C2 (de) 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
DE3248588A1 (de) 1982-12-30 1984-07-12 Nordmark-Werke Gmbh, 2000 Hamburg Verfahren zur gewinnung von pankreatin von hohem schuettgewicht
CA2030581C (en) * 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
TW310277B (en) † 1993-05-21 1997-07-11 Pou Lin Fu Gin Pharm Co The method of preparing enteric-coated pancreatin granules and its dosage forms
KR19990072826A (ko) * 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
RU2381813C2 (ru) * 2004-03-22 2010-02-20 Зольвай Фармасьютиклз Гмбх Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав
ES2614157T3 (es) 2004-10-14 2017-05-29 Eli Lilly And Co. Composiciones que contienen lipasa, proteasa y amilasa para el tratamiento de la insuficiencia pancreática
US11266607B2 (en) † 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
AU2006281415B2 (en) 2005-08-15 2012-01-19 Abbott Laboratories Gmbh Pancreatin micropellet cores suitable for enteric coating
WO2008127567A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
ES2488407T3 (es) 2009-01-29 2014-08-27 Nordmark Arzneimittel Gmbh & Co. Kg Preparación farmacéutica que contiene lipasa de origen bacteriano
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
PL2489349T3 (pl) * 2011-02-17 2014-09-30 Nordmark Arzneimittel Gmbh & Co Kg Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji

Also Published As

Publication number Publication date
EP2295039B2 (de) 2022-10-26
US20110052706A1 (en) 2011-03-03
DE202010004926U1 (de) 2010-07-29
JP5761635B2 (ja) 2015-08-12
JP2011046682A (ja) 2011-03-10
BRPI1000679A2 (pt) 2011-05-17
EP2295039B1 (de) 2013-12-11
EP2295039A1 (de) 2011-03-16
US8999394B2 (en) 2015-04-07
PL2295039T5 (pl) 2023-02-27

Similar Documents

Publication Publication Date Title
PL2295039T5 (pl) Sposób wytwarzania granulek zawierających pankreatynę, w szczególności mikrogranulek zawierających pankreatynę, oraz wytworzone tym sposobem granulki zawierające pankreatynę
IL272848B (en) Methods for reprogramming cells and their use
SG10201505887VA (en) Liver organoid, uses thereof and culture method for obtaining them
EP2623545A4 (en) CELLULOSE SPUTTERING METHOD, CELLULOSE NANOFIBERS, MASTER MIXTURE, AND RESIN COMPOSITION
GB2475452B (en) Four point utility blade and method
EP2602081A4 (en) RESIN FORM, METHOD FOR THEIR PRODUCTION AND THEIR USE
EP2345685A4 (en) POLYMER AND METHOD FOR PREPARING THE SAME
IL210210A0 (en) Improved protein production and storage in plants
GB201001544D0 (en) Pellets and process therefor
EP2525678A4 (en) Improved molding system, method and articles formed thereby
HK1208489A1 (en) Fuel pellet, fuel pellet production method, and fuel pellet production device
PL2457412T3 (pl) Jednostka grzejna, w szczególności wysokotemperaturowa jednostka grzejna jak też sposób jej wytwarzania
HK1159688A1 (en) Freeze-dried microbial cell powder and method for producing same
EP2500858A4 (en) CONSTRUCTION PROCESS CREATION SYSTEM AND METHOD FOR CREATING CONSTRUCTION PROCESS
EP2407886A4 (en) SIMULATION PROCESS, SYSTEM AND PROGRAM
GB2486136B (en) Simulation method, system, and program
EP2660264A4 (en) PHOTOVOLTAIC POLYMER MATERIAL, METHOD FOR THE PRODUCTION AND USE THEREOF
PL2489349T3 (pl) Granulki pankreatynowe, zwłaszcza mikrogranulki pankreatynowe, oraz sposób ich produkcji
ZA201300164B (en) Improved method for producing cellulolytic and/or hemicellulolytic enzymes
EP2395009A4 (en) POLYLACTIDE RESIN AND METHOD OF MANUFACTURING THEREOF
IL218026A0 (en) Processes for culturing prokaryotic cells, cells produced thereby and uses thereof
PT2443227T (pt) Levedura, método de preparação, composição, equipamento e utilizações
GB2483829B (en) Messaging system and method
GB0906992D0 (en) Cells, preparation, uses, methods and components
AU2009903125A0 (en) Improved hot water storage means and method